Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Price Drop

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Jan 17, 2022 6:13pm

175 Views

Post# 34326361

RE:RE:RE:Price Drop

My guess is you haven't watched the webinar today? Because that is by far the most relevant information. IMO, the primary menace for Algernon stock was Kulwant Malhi. It's said Algernon is now out of his millions of shares stock flipping portfolio. To date, the stock is moving ^up and ^up. What's your break even point/catalyst to suggest manipulation is no longer a problem? For me, it's all about the uplist to a higher regulated exchange - NASDAQ. Problem likely re/solved.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?